Jump to Main Content
Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
- Binnewies, Mikhail, Mujal, Adriana M., Pollack, Joshua L., Combes, Alexis J., Hardison, Emily A., Barry, Kevin C., Tsui, Jessica, Ruhland, Megan K., Kersten, Kelly, Abushawish, Marwan A., Spasic, Marko, Giurintano, Jonathan P., Chan, Vincent, Daud, Adil I., Ha, Patrick, Ye, Chun J., Roberts, Edward W., Krummel, Matthew F.
- Cell 2019 v.177 no.3 pp. 556-571.e16
- CD4-positive T-lymphocytes, antigens, dendritic cells, immunity, lymph nodes, melanoma, mice, patients, phenotype, therapeutics, traffic
- Differentiation of proinflammatory CD4+ conventional T cells (Tconv) is critical for productive antitumor responses yet their elicitation remains poorly understood. We comprehensively characterized myeloid cells in tumor draining lymph nodes (tdLN) of mice and identified two subsets of conventional type-2 dendritic cells (cDC2) that traffic from tumor to tdLN and present tumor-derived antigens to CD4+ Tconv, but then fail to support antitumor CD4+ Tconv differentiation. Regulatory T cell (Treg) depletion enhanced their capacity to elicit strong CD4+ Tconv responses and ensuing antitumor protection. Analogous cDC2 populations were identified in patients, and as in mice, their abundance relative to Treg predicts protective ICOS+ PD-1lo CD4+ Tconv phenotypes and survival. Further, in melanoma patients with low Treg abundance, intratumoral cDC2 density alone correlates with abundant CD4+ Tconv and with responsiveness to anti-PD-1 therapy. Together, this highlights a pathway that restrains cDC2 and whose reversal enhances CD4+ Tconv abundance and controls tumor growth.